Table 2 Demographic and clinical characteristics of individuals with metastatic melanoma
Total (N = 12,028) | Without autoimmune conditions (n = 9048) | With autoimmune conditions (n = 2980) | P-value | |
|---|---|---|---|---|
Age, mean (SD)a | 64.2 (14.2) | 63.9 (14.4) | 65.2 (13.6) | < 0.0001 |
Age group, n (%)a | < 0.0001 | |||
18–34 | 289 (2.4) | 235 (2.6) | 54 (1.8) | |
35–54 | 2614 (21.7) | 2049 (22.7) | 565 (19.0) | |
55–64 | 3553 (29.5) | 2651 (29.3) | 902 (30.3) | |
65–74 | 2304 (19.2) | 1681 (18.6) | 623 (20.9) | |
≥ 75 | 3268 (27.2) | 2432 (26.9) | 836 (28.1) | |
Gender, n (%)a | < 0.0001 | |||
Male | 7574 (63.0) | 5824 (64.4) | 1750 (58.7) | |
Female | 4454 (37.0) | 3224 (35.6) | 1230 (41.3) | |
Health insurance plan, n (%)a | 0.042 | |||
Comprehensive | 2799 (23.3) | 2109 (23.3) | 690 (23.2) | |
HMO | 1429 (11.9) | 1120 (12.4) | 309 (10.4) | |
POS | 578 (4.8) | 438 (4.8) | 140 (4.7) | |
PPO | 6058 (50.4) | 4520 (50.0) | 1538 (51.6) | |
Others | 1164 (9.7) | 861 (9.5) | 303 (10.2) | |
Medicare beneficiaries, n (%)a | 0.007 | |||
Yes | 5517 (45.9) | 4086 (45.2) | 1431 (48.0) | |
No | 6511 (54.1) | 4962 (54.8) | 1549 (52.0) | |
Regions, n (%) | 0.109 | |||
North East | 1760 (14.6) | 1296 (14.3) | 464 (15.6) | |
North Central | 3065 (25.5) | 2320 (25.6) | 745 (25.0) | |
South | 4165 (34.6) | 3180 (35.2) | 985 (33.1) | |
West | 2549 (21.2) | 1888 (20.9) | 661 (22.2) | |
Unknown/Other | 489 (4.1) | 364 (4.0) | 125 (4.2) | |
Metastasis site, n (%)a | < 0.0001 | |||
Brain | 2082 (17.3) | 1551 (17.1) | 531 (17.8) | |
Bone | 1541 (12.8) | 1044 (11.5) | 497 (16.7) | |
Liver | 1109 (9.2) | 814 (9.0) | 295 (9.9) | |
Gastro-intestinal system | 386 (3.2) | 269 (3.0) | 117 (3.9) | |
Lungs | 1372 (11.4) | 1042(11.5) | 330 (11.1) | |
Charlson comorbidity score, mean (SD)a | < 0.0001 | |||
0.6 (1.0) | 0.5 (0.9) | 0.9 (1.3) | ||
Charlson Category, N (%)a | < 0.0001 | |||
0 | 8038 (66.8) | 6477 (71.6) | 1561 (52.4) | |
1 | 2430 (20.2) | 1687 (18.7) | 743 (24.9) | |
≥ 2 | 1560 (13.0) | 884 (9.8) | 676 (22.7) | |